Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

August 18, 2027

Study Completion Date

August 18, 2027

Conditions
Influenza PreventionPandemic Influenza Prevention
Interventions
BIOLOGICAL

VRC-FLUMOS0122-00-VP (SteMos1) with and without Army Liposome Formulation containing saponin QS-21 (ALFQ) Adjuvant

"FLUMOS0122-00-VP (SteMos1) is a sterile, aqueous buffered solution supplied in 3 mL single-dose glass vials containing 0.7 +/- 0.1 mL with a vaccine concentration of 1080 mcg/mL.~The ALFQ drug product is a sterile suspension that contains 240 mcg of monophosphoryl 3-deacyl Lipid A (3D-PHAD) and 120 mcg QS-21 that is vialed at 0.6 mL/vial in 3.0 mL glass vials. 0.5 mL of ALFQ adjuvant will be mixed with the 60 or 180 mcg dose of SteMos1 during preparation in the pharmacy prior to"

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH